Filtered By:
Specialty: Cardiology
Condition: Cholesterol
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 2240 results found since Jan 2013.
Optimization of secondary prevention in patients with high-risk atherothrombotic ischemic stroke or transient ischemic attacks
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(6):36-43. doi: 10.17116/jnevro202312306136.ABSTRACTHigh and very high risk atherothrombotic ischemic stroke (ATIS) includes patients with severe extracranial atherosclerosis, any intracranial atherosclerosis, and aortic arch atheromatosis. The article discusses the most effective approaches to medical short- and long-term secondary prevention of ATIS, major vascular events and death, based on the results of modern research and current clinical guidelines. Clinical studies of recent years have proven the possibility of individualization and intensification of secondary preventi...
Source: Atherosclerosis - June 29, 2023 Category: Cardiology Authors: A A Kulesh S N Yanishevskiy D A Demin L I Syromyatnikova O I Vinogradov Source Type: research
Reply to "Correspondence to: Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis"
Atherosclerosis. 2023 Jun 22:S0021-9150(23)04098-4. doi: 10.1016/j.atherosclerosis.2023.06.968. Online ahead of print.NO ABSTRACTPMID:37380541 | DOI:10.1016/j.atherosclerosis.2023.06.968
Source: Atherosclerosis - June 28, 2023 Category: Cardiology Authors: Xiu Hong Yang Bao Long Zhang Hui Min Jin Source Type: research
More Than 50 Percent Reduction in LDL Cholesterol in Patients With Target LDL & lt;70 mg/dL After a Stroke
CONCLUSIONS: In this post hoc analysis of the TST trial, targeting an LDL cholesterol of <70 mg/dL reduced the risk of primary outcome compared with 100±10 mg/dL provided LDL cholesterol reduction from baseline was superior to 50%, thereby suggesting that the magnitude of LDL cholesterol reduction was as important to consider as the target level to achieve.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875; https://clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:37376989 | DOI:10.1161/STROKEAHA.123.042621
Source: Atherosclerosis - June 28, 2023 Category: Cardiology Authors: Pierre Amarenco Philippa C Lavall ée Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats
CONCLUSIONS: Overall, the XO inhibitor febuxostat exerted protective effects against NASH and atherosclerosis in SHRSP5/Dmcr rats.PMID:37376883 | DOI:10.32725/jab.2023.009
Source: Atherosclerosis - June 28, 2023 Category: Cardiology Authors: Mai Kakimoto Moe Fujii Ikumi Sato Koki Honma Hinako Nakayama Sora Kirihara Taketo Fukuoka Shang Ran Satoshi Hirohata Kazuya Kitamori Shusei Yamamoto Shogo Watanabe Source Type: research
Insulin Regulation of Hepatic Lipid Homeostasis
Compr Physiol. 2023 Jun 26;13(3):4785-4809. doi: 10.1002/cphy.c220015.ABSTRACTThe incidence of obesity, insulin resistance, and type II diabetes (T2DM) continues to rise worldwide. The liver is a central insulin-responsive metabolic organ that governs whole-body metabolic homeostasis. Therefore, defining the mechanisms underlying insulin action in the liver is essential to our understanding of the pathogenesis of insulin resistance. During periods of fasting, the liver catabolizes fatty acids and stored glycogen to meet the metabolic demands of the body. In postprandial conditions, insulin signals to the liver to store exc...
Source: Atherosclerosis - June 26, 2023 Category: Cardiology Authors: Kahealani Uehara Dominic Santoleri Anna E Garcia Whitlock Paul M Titchenell Source Type: research
Reply to “Correspondence to: Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis”
We sincerely appreciate Dr. Athanasopoulou ’ s comments in response to our meta-analysis [1]. We agree with most of his opinions and would like to clarify our views here.
Source: Atherosclerosis - June 22, 2023 Category: Cardiology Authors: Xiu Hong Yang, Bao Long Zhang, Hui Min Jin Tags: Correspondence Source Type: research
Neuroprotector Hopeful in Stroke; Late-Pandemic STEMIs; Exercise vs Risky Carotids?
(MedPage Today) -- In the CLEAR Outcomes trial, bempedoic acid (Nexletol) reduced cardiac events to a similar extent as statins, according to a secondary analysis presented at ENDO 2023.
The TLR4 antagonist ApTOLL showed promise as a neuroprotectant...
Source: MedPage Today Cardiovascular - June 20, 2023 Category: Cardiology Source Type: news
A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
Front Pharmacol. 2023 May 30;14:1204905. doi: 10.3389/fphar.2023.1204905. eCollection 2023.ABSTRACTAtherosclerosis is a chronic inflammatory disease of the arterial walls that develops at predisposed sites. As a major risk factor for adverse cardiovascular pathology, atherosclerosis can progress to myocardial infarction and stroke, due to the rupture of unstable atherosclerotic lesions. Macrophage uptake of modified lipoproteins and metabolic dysfunction contributes significantly to the initiation and development of atherosclerotic lesions. The cluster of differentiation 36 receptor [CD36 (SR-B2)] plays a key role in ather...
Source: Atherosclerosis - June 19, 2023 Category: Cardiology Authors: Jade Gauvin Genevi ève Frégeau Hanan Elimam Liliane M énard David Huynh Catherine L ê Ahsanullah Ahsanullah William D Lubell Huy Ong Sylvie Marleau Source Type: research
Correspondence to: "Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis"
Atherosclerosis. 2023 Jun 5:S0021-9150(23)00226-5. doi: 10.1016/j.atherosclerosis.2023.05.021. Online ahead of print.NO ABSTRACTPMID:37336677 | DOI:10.1016/j.atherosclerosis.2023.05.021
Source: Atherosclerosis - June 19, 2023 Category: Cardiology Authors: Elpida Athanasopoulou Athanase D Protogerou Source Type: research
Association and mediating mechanism between remnant cholesterol and first-ever stroke among the Chinese general population
CONCLUSION: High RC increased the risk of first-ever stroke in the Chinese general population without previous stroke and myocardial infarction, partially through the pathway of hypertension. RC might be a potential target for the primary prevention of stroke.PMID:37304024 | PMC:PMC10247974 | DOI:10.3389/fnins.2023.1161367
Source: Atherosclerosis - June 12, 2023 Category: Cardiology Authors: Heng Li Shuai Miao Lu Chen Bin Liu Yan-Bin Li Rui-Sheng Duan Source Type: research
Investigation of Combined Carotid Endarterectomy and Coronary Artery Bypass Graft Surgery Outcomes and Adverse Event Risk Factors in the Vascular Quality Initiative
CONCLUSIONS: Combined CEA and CABG provides excellent long-term mortality prevention in patients with co-existing severe coronary and carotid atherosclerosis. Simultaneous CEA and CABG provides equivalent stroke prevention and long-term survival to both a cohort of patients undergoing coronary revascularization within 5 years of CEA and patients undergoing isolated CEA or CABG in the literature. The two most impactful modifiable risk factors towards long-term stroke and mortality prevention for patients undergoing simultaneous CEA-CABG are patch placement at CEA site and adherence to statin medication therapy.PMID:37303074...
Source: Atherosclerosis - June 11, 2023 Category: Cardiology Authors: Ashley Penton Jonathan Lin Grant Kolde Matthew DeJong Matthew Blecha Source Type: research
Plain language summary of results from ORION-10 and ORION-11: Two studies to learn how well inclisiran works in people with high cholesterol
Future Cardiol. 2023 Jun 6. doi: 10.2217/fca-2022-0133. Online ahead of print.ABSTRACTWHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT?: This is a summary of the article describing the results of the ORION-10 and ORION-11 studies, which was published in the New England Journal of Medicine in April 2020. The studies included adult participants with atherosclerotic cardiovascular disease (ASCVD). ASCVD happens when the blood vessels that carry blood from the heart to other areas of the body are blocked by fatty build-up (plaque) causing a heart attack, stroke, or other problems. High levels of low-density lipoprotein cholesterol (L...
Source: Atherosclerosis - June 7, 2023 Category: Cardiology Authors: Kausik K Ray R Scott Wright Source Type: research
